Resumen de acción IMM Immutep Limited, empresa biotecnológica en fase avanzada, se dedica a desarrollar en Australia nuevas inmunoterapias relacionadas con el LAG-3 para el cáncer y las enfermedades autoinmunes. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Immutep Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Immutep Precios históricos de las acciones Precio actual de la acción AU$0.36 Máximo en las últimas 52 semanas AU$0.48 Mínimo de 52 semanas AU$0.23 Beta 1.93 Cambio en 1 mes 10.77% Variación en 3 meses 14.29% Cambio de 1 año 7.46% Variación en 3 años -24.21% Variación en 5 años 26.32% Variación desde la OPV 0%
Noticias y actualizaciones recientes
Less than half of directors are independent Dec 24
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 Dec 18
Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II Dec 16
Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024 Dec 12
Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer Dec 10
Immutep Limited, Annual General Meeting, Nov 22, 2024 Oct 10 Ver más actualizaciones
Less than half of directors are independent Dec 24
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 Dec 18
Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II Dec 16
Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024 Dec 12
Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer Dec 10
Immutep Limited, Annual General Meeting, Nov 22, 2024 Oct 10
Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director Oct 04
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer Oct 03
Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma Sep 19
Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha Sep 16
Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.045 loss in FY 2023) Aug 30
No longer forecast to breakeven Aug 30
Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress Aug 21
Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody Aug 14
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer Jul 23
Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases Jul 17
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression Jul 12
New minor risk - Shareholder dilution Jun 13
No longer forecast to breakeven Jun 05
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial Jun 05
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024 May 16
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma May 03
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B Apr 27
New minor risk - Profitability Apr 25
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 Apr 20
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer Apr 17
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti Mar 05
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer Jan 05
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer Dec 21
Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma Nov 10
Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer Nov 04
Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023 Oct 25
Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha Oct 23
Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use Sep 22
Immutep Limited, Annual General Meeting, Oct 24, 2023 Sep 08
Full year 2023 earnings released: AU$0.045 loss per share (vs AU$0.038 loss in FY 2022) Aug 31 Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha Aug 03
Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma Jul 29
Forecast to breakeven in 2026 Jun 30 Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer May 18 Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer May 17
No longer forecast to breakeven Mar 14
First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022) Feb 25
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC Feb 07
Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC Feb 06
Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial Jan 04 Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration Dec 24
Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha Dec 10
Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease Dec 06
Less than half of directors are independent Nov 17 Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned Oct 27
Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha Oct 06
Immutep Limited, Annual General Meeting, Nov 23, 2022 Sep 21 Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha Sep 15
Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha Sep 14
Immutep Appoints Frederic Triebel as Executive Director Sep 13
Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma Sep 07
Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma Sep 06
No longer forecast to breakeven Sep 02
Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor Aug 31
Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC Aug 02
Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022 Jul 29
Forecast to breakeven in 2025 Jul 01
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers Jun 04
High number of new and inexperienced directors Jun 03
Immutep Limited Announces Executive Changes May 18
Immutep Limited Presents New and Significant Data from the AIPAC Study May 05
Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022 May 02
Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients Mar 31
Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial Mar 30
High number of new directors Mar 29
First half 2022 earnings: EPS in line with expectations, revenues disappoint Mar 01
Immutep Limited Appoints Lucy Turnbull as Non-Executive Director Feb 25
Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022 Feb 19
Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti At ESMO's European Lung Cancer Congress 2022 Feb 18
Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director Feb 02
Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha Jan 26
No longer forecast to breakeven Jan 06
Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study Dec 03
Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021 Sep 23
Forecast to breakeven in 2024 Sep 23
Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.034 loss in FY 2020) Sep 02
Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates Jul 15
Immutep Receives FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC Jul 07
Forecast to breakeven in 2024 Jun 30 Immutep Limited Signs Agreement to Commence New Phase I Trial, Called Insight-003, to Evaluate the Combination of Lead Product Candidate Eftilagimod Alpha
Immutep Limited Reveals a New anti-LAG-3 Research Program Jun 08
Immutep Limited Reports Positive Data from Its Tacti-002 Phase Ii Study of Lag-3 Therapy, Efti, At Asco 2021 Jun 05
Immutep Limited Reports Positive Final Data from Insight-004 Trial Jun 04
Immutep Limited Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting May 21 Rentabilidad de los accionistas IMM AU Biotechs Mercado AU 7D 5.9% 0.6% -0.6% 1Y 7.5% 4.2% 7.4%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: IMM superó a la industria Australian Biotechs, que obtuvo un rendimiento del 4.2% el año pasado.
Rentabilidad vs. Mercado: IMM igualó el mercado Australian, que obtuvo un rendimiento del 7.4% el año pasado.
Volatilidad de los precios Is IMM's price volatile compared to industry and market? IMM volatility IMM Average Weekly Movement 7.3% Biotechs Industry Average Movement 9.9% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.0%
Precio estable de las acciones: IMM no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de IMM (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Immutep Limited, empresa biotecnológica en fase avanzada, se dedica a desarrollar en Australia nuevas inmunoterapias relacionadas con LAG-3 para el cáncer y las enfermedades autoinmunes. Su principal producto candidato es el eftilagimod alfa (efti o IMP321), una fusión soluble basada en LAG-3lg, que está en fase de desarrollo clínico para el tratamiento de distintos tipos de cáncer. La cartera de productos de la empresa también incluye TACTI-004, en fase III de ensayo clínico para el tratamiento del cáncer de pulmón no microcítico de primera línea (CPNM 1L); TACTI-003, en fase IIb de ensayo clínico para tratar el carcinoma escamoso de cabeza y cuello (CECC) de primera línea; TACTI-002, que está en fase II de ensayo clínico para el tratamiento del CPNM y el HNSCC; AIPAC-003, que está en fase II/III de ensayo clínico para tratar el cáncer de mama metastásico; y EFTISARC-NEO, que está en fase II de ensayo clínico para el tratamiento del sarcoma de tejidos blandos.
Mostrar más Resumen de fundamentos de Immutep Limited ¿Cómo se comparan los beneficios e ingresos de Immutep con su capitalización de mercado? Estadísticas fundamentales de IMM Capitalización bursátil AU$516.37m Beneficios(TTM ) -AU$42.72m Ingresos (TTM ) AU$3.84m
134.4x Ratio precio-ventas (PS)
-12.1x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de IMM Ingresos AU$3.84m Coste de los ingresos AU$41.55m Beneficio bruto -AU$37.70m Otros gastos AU$5.01m Beneficios -AU$42.72m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.029 Margen bruto -981.42% Margen de beneficio neto -1,111.87% Ratio deuda/patrimonio 0.5%
¿Cómo se ha desempeñado IMM a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/02 19:28 Precio de las acciones al final del día 2025/01/02 00:00 Beneficios 2024/06/30 Ingresos anuales 2024/06/30
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Immutep Limited está cubierta por 17 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Joel Beatty Baird Thomas Wakim Bell Potter Tara Speranza Bell Potter
Mostrar 14 más analistas 
